Cardiac DiseaseFISICH-INCT03946956
Fighting Social Inequality in Cardiovascular Health I
A study testing Prebooking and Pictured invitation in people with Cardiac Disease and Vascular Diseases, run by Odense University Hospital at 5 sites in Denmark.
Trial summary
This study attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease (CVD) among people with low social status Read more about this study
- Who is it for?
- Ages 60 to 65 years, men only
- Conditions the study is for
- Cardiac Disease, Vascular Diseases
- What is being tested?
- Prebooking and Pictured invitation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 5,000 participants
- Where
- 5 sitesDenmark
- Study dates
- 1 Aug 2017to 31 Mar 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 to 65 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Men aged 60-64 living in the municipalities of Funen, Silkeborg, Vejle and surrounding municipailties
Who cannot join
- Men not aged 60-65
- Men not living in the mentioned municipalities
- Women
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Denmark5 sites
Nykøbing Falster Sygehus
Nykøbing Falster, 4800
Odense University Hospital
Odense, 5000
Region Hospital Silkeborg
Silkeborg, 8600
Svendborg Sygehus
Svendborg, 5700
Vejle Hospital
Vejle, 7100
About this study
This study attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease (CVD) among people with low social status
Read the detailed description
Background
Although CVDs have decreased, they are still among the most predominant cause of morbidity and mortality in the western world, incl. Denmark, where about 420,000 people have recognized CVD symptoms. Due to an aging population, the decline has not reduced CVD admissions and healthcare costs.
In Denmark, the CVD related hospital admission costs are DKK 4.6 billion and the pharmaceutical cost DKK 2.4 billion. The Danish National Board of Health has reported that CVD carries the second largest socioeconomic difference in burden of disease. Unfortunately, population-based health checks and screening for risk factors has proven not efficient. Consequently, screening of asymptomatic CVD is discussed intensively. In the investigators first unique CVD screening RCT (2008-11), the VIVA trial, they randomized more than 50.000 65-74 year old men for population-based ultrasound screening for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD) and hypertension. In case of positive finding, preventive medical actions were initiated. A significant reduction in overall mortality by 7% after 5 years was observed (paper submitted). Using a non-contrast CT scan, instead of the ultrasound based screening approach, has the opportunity to identify aneurysms in the entire aortic, coronary artery calcification (CAC) and arterial fibrillation, so individualized risk assessment and initiation of preventive actions on those with sign of early asymptomatic CVD is possible. The investigators therefore initiated a second trial (DANCAVAS) in 2014 randomizing 45.000 65-74 year old men with the potential of a huge beneficial effect on health, quality of life (QoL) and survival. However, screening is impaired by lower social class, and adherence to initiated prevention could be impacted as well. Consequently, they want to conduct a third RCT (FISICH) to test a number of add-ons to screening that potentially balance the benefits across socio economic groups.
The perspective is to establish a clear decision foundation for public health care policy incl. benefits, cost effectiveness and impact on social inequality of alternative variants of population screening for CVD.
Hypotheses The primary hypothesis is that an extensive circulatory screening and intervention programme reduces social inequality in cardiovascular health and fulfills the WHO criteria for screening. However, this reduction can be even more pronounced, if factors reducing the social selection to attend screening and adherence to preventive actions initiated are identified.
Aims
The aims are to
- Test whether prebooking and/or supplemental informative pictures of the screening session and consultation improves attendance rate in general, and particular among those with the lowest educational level, lowest income level, and psychiatric disease.
- Investigate whether confrontation of imaging of own arterial lesions at consultation after screening and/or an e-mail 3 and 12 months after the consultation in case of positive findings improves adherence to suggested cardiovascular preventive actions, and whether it influences quality of life, in general and especially concerning those with the lowest educational level, lowest income level, and psychiatric disease.
Materials and methods
In FISICH-I 20.000 60-64 year old men are randomized to the control group, while another 5.000 are randomized to the screening and intervention program for CAC, aortic and iliac aneurysms, atrial fibrillation, PAD, hypertension, diabetes and hypercholesterolaemia. There is no exclusion criteria. The screening setup is similar to DANCAVAS:
- A small questionnaire on life style, medical history, and the QoL a.o. will be enclosed with the invitation. Non-responders are re-invited once.
- The participant will be informed at attendance to the screening visit, and their consent will be obtained together with the questionnaire, weight, height, and waist circumference.
- The CT scan will cover the area from the mandibular bone distally to the proximal third of the femur. Calcium scores for the common carotids, coronary arteries, aorta, and common iliac, and femoral arteries will be calculated. The aorta are visualized, and the diameter is measured in ascending, arcus, descending and abdominal, and if possible in the iliac arteries. Further the heart rhythm during the CT scan is evaluated.
- Bilateral blood pressure will be recorded three times after 5 minutes of supine rest, and concurrently the ankle blood pressure are measured.
- The HbA1c and lipid parameters will be measured. Biobank blood samples are then taken, centrifuged, labelled, cooled, and stored at -80 degrees Celsius.
Follow-up visit after screening If the CAC is above the median or if an aneurism of peripheral arterial disease are detected the participant is informed of the finding and its implications at a follow-up visit. At this visit, the patient will be recommended suitable prophylactic measures, including smoking cessation, walking/exercise, a lowfat diet. Additionally to start treatment with aspirin 75 mg/day and atorvastatin 40 mg/day. If an aneurism is large the patient is referred vascular surgical assessment for the repair. Otherwise, an annual check-up of the aneurism including a CT scan will be offered. If no positive findings (CAC above the median, aneurysm or PAD) are detected, the participants will be informed of the findings by e-mail or ordinary post as preferred.
Independent of the above findings, the patients will be encouraged to see their GP for further assessment if potential undiagnosed hypertension (systolic blood pressure >160 mmHg), diabetes mellitus (HbA1c >48 mmol/mol), or significant isolated hypercholesterolemia (total-cholesterol >8.0 mmol/l) are observed, as possible continuous medical treatments will be better managed by the GPs.
The GPs will be informed by a letter of all negative and positive results and the initiated actions. Additionally in the FISICH-I trial, four further randomizations are performed. In the written invitations to the screening examination two further randomizations are performed;
- prebooking versus active booking
- +/- addition of illustrations of the examinations during the screening session.
Power calculations and Randomisations
Randomisation will be performed in SPSS by providing each individual a random number from 1-20. Those numbered +16 will be invited to participate in the screening program. Those numbered 17 and 18 will be prebooked, while those numbered 19 and 20 will have to book themselves through web-booking, email or phone.
Those with an equal number (18 and 20) will receive supplemental informative pictures of the screening session.
In case of positive finding a new random number from 1-4 is given. Those numbered 3 and 4 will be confronted with imaging of their own arterial lesions, whilst others will receive standard information. Those with an equal number (2 and 4) will receive a SMS, e-mail and phone call 3 \& 12 months after the consultation. If all groups after randomisations are equally sized,- 182 will only be additionally randomized to be remembered prescription renewal after 3 and 12 months, and 182 will only have been randomized to the standard of booking (Control group for all invited). If 12 months compliance to initiated preventive medication is 66%, then with 0.05 significance level, and 80% power, the smallest difference detectable is 15%, which seems clinical relevant. However, merged analyses adjusting for the other interventions will be performed reducing the smallest detectable difference and reveal potential synergistic combinations. Similar group comparisons will be performed for all randomized interventions.
Baseline variables Age, smoking, previous or current stroke, ischemic heart disease, PAD, chronic obstructive pulmonary disease, diabetes, hypertension, use of statins, useof antithrombotics, body mass index, systolic- and diastolic blood pressure, ankle brachial index, marital status, highest educational level, personal- andin house income, psychiatric morbidity defined as any diagnosis and/or use of medications for mental illness, and QoL.
Baseline and outcome variables from national registries The CPR number assigned to Danish citizens enables individual-level linkage to multiple nation-wide healthcare and administrative registries which have proved valid.
Registry-based information on outpatient visits, hospitals admissions and procedures (The Danish National Patient Registry), relevant prescribed drugs dispensed (The Danish National Prescription Registry), socio economic status etc. (Registries at Statistics Denmark) and primary care service use (National Health Insurance Service Registry) will be obtained.
Outcomes The primary outcomes are
- Attendance to screening
- One-year adherence to initiated lipid-lowering and/or antithrombotic medication.
Secondary outcome is:
- QoL,
Statistical analysis Baseline characteristics will be analysed using conventional summary statistics.
Attendance rates adjusted for invitation layout and booking-method, as well as compliance one year after initiation (def.: received a prescription 9-12 months after the consultation) adjusted for image-confrontation and post-consultation phone call are compared by logistic regression analysis.
- Conditions
- Cardiac Disease, Vascular Diseases
- Being tested
- Prebooking, Pictured invitation
- Keywords
- Screening, Prevention, Cardiovascular, Public health
- Medical subject headings
- Heart Diseases, Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PrebookingBehavioural
Participants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening
Pictured invitationBehavioural
Participants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening
| Study group | Role | What they receive |
|---|---|---|
| Prebooking | Active comparator | Participants randomised to this arm receives a prebooked appointment to screening Receives: Behavioral: Prebooking; Behavioral: Pictured invitation |
| Web based booking | Placebo comparator | Participants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office. Receives: Behavioral: Prebooking; Behavioral: Pictured invitation |
| Pictured invitation | Active comparator | Participants randomised to this arm receives a pictured invitation to screening Receives: Behavioral: Prebooking; Behavioral: Pictured invitation |
| Texted invitation | Placebo comparator | Participants randomised to this arm receives a classical texted invitation to screening Receives: Behavioral: Prebooking; Behavioral: Pictured invitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Attendance rate to screening
The proportion of invited attending screening
Measured: 6 months
Secondary outcomes (1)
Quality of Life of invitation to screening
Quality of life measured by EurQol 5D
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 May 2019
- Study start1 Aug 2017
- Primary completion31 Mar 2019
- Study completion31 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac DiseaseStudies of the same condition, open and under way.
- More trials run by Odense University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- 2 x factorial design regarding attendance rate to cardiovacular screening
- Masking
- None (open label)
- Enrolment
- 5,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- Odense University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Regionshospitalet Silkeborg, Vejle Hospital, Svendborg Hospital, Nykøbing Falster Hospital
- Responsible party
- Principal investigator, Jes Lindholt, Odense University Hospital
- Investigators
- Jes S Lindholt, Principal investigator, Odense University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03946956
- Sponsor's protocol ID
- S20160164a
- Acronym
- FISICH-I
- Status last verified
- May 2019
- First submitted
- 9 May 2019
- Last updated
- 14 May 2019
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Data will be analysed on Statistics Denmarks secured server
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fighting Social Inequality in Cardiovascular Health I
- ClinicalTrials.gov ID
- NCT03946956
- Acronym / sponsor ID
- FISICH-I / S20160164a
- Conditions
- Cardiac Disease, Vascular Diseases
- Keywords
- Screening, Prevention, Cardiovascular, Public health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5,000 participants (actual)
- Lead sponsor
- Odense University HospitalUniversity, hospital or other
- Collaborators
- Regionshospitalet Silkeborg, Vejle Hospital, Svendborg Hospital, Nykøbing Falster Hospital
- Study start
- 1 Aug 2017 (actual)
- Primary completion
- 31 Mar 2019 (actual)
- Study completion
- 31 Mar 2019 (actual)
- First posted
- 13 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease (CVD) among people with low social status
Detailed description
Background
Although CVDs have decreased, they are still among the most predominant cause of morbidity and mortality in the western world, incl. Denmark, where about 420,000 people have recognized CVD symptoms. Due to an aging population, the decline has not reduced CVD admissions and healthcare costs.
In Denmark, the CVD related hospital admission costs are DKK 4.6 billion and the pharmaceutical cost DKK 2.4 billion. The Danish National Board of Health has reported that CVD carries the second largest socioeconomic difference in burden of disease. Unfortunately, population-based health checks and screening for risk factors has proven not efficient. Consequently, screening of asymptomatic CVD is discussed intensively. In the investigators first unique CVD screening RCT (2008-11), the VIVA trial, they randomized more than 50.000 65-74 year old men for population-based ultrasound screening for abdominal aortic aneurysm (AAA), peripheral arterial disease (PAD) and hypertension. In case of positive finding, preventive medical actions were initiated. A significant reduction in overall mortality by 7% after 5 years was observed (paper submitted). Using a non-contrast CT scan, instead of the ultrasound based screening approach, has the opportunity to identify aneurysms in the entire aortic, coronary artery calcification (CAC) and arterial fibrillation, so individualized risk assessment and initiation of preventive actions on those with sign of early asymptomatic CVD is possible. The investigators therefore initiated a second trial (DANCAVAS) in 2014 randomizing 45.000 65-74 year old men with the potential of a huge beneficial effect on health, quality of life (QoL) and survival. However, screening is impaired by lower social class, and adherence to initiated prevention could be impacted as well. Consequently, they want to conduct a third RCT (FISICH) to test a number of add-ons to screening that potentially balance the benefits across socio economic groups.
The perspective is to establish a clear decision foundation for public health care policy incl. benefits, cost effectiveness and impact on social inequality of alternative variants of population screening for CVD.
Hypotheses The primary hypothesis is that an extensive circulatory screening and intervention programme reduces social inequality in cardiovascular health and fulfills the WHO criteria for screening. However, this reduction can be even more pronounced, if factors reducing the social selection to attend screening and adherence to preventive actions initiated are identified.
Aims
The aims are to
- Test whether prebooking and/or supplemental informative pictures of the screening session and consultation improves attendance rate in general, and particular among those with the lowest educational level, lowest income level, and psychiatric disease.
- Investigate whether confrontation of imaging of own arterial lesions at consultation after screening and/or an e-mail 3 and 12 months after the consultation in case of positive findings improves adherence to suggested cardiovascular preventive actions, and whether it influences quality of life, in general and especially concerning those with the lowest educational level, lowest income level, and psychiatric disease.
Materials and methods
In FISICH-I 20.000 60-64 year old men are randomized to the control group, while another 5.000 are randomized to the screening and intervention program for CAC, aortic and iliac aneurysms, atrial fibrillation, PAD, hypertension, diabetes and hypercholesterolaemia. There is no exclusion criteria. The screening setup is similar to DANCAVAS:
- A small questionnaire on life style, medical history, and the QoL a.o. will be enclosed with the invitation. Non-responders are re-invited once.
- The participant will be informed at attendance to the screening visit, and their consent will be obtained together with the questionnaire, weight, height, and waist circumference.
- The CT scan will cover the area from the mandibular bone distally to the proximal third of the femur. Calcium scores for the common carotids, coronary arteries, aorta, and common iliac, and femoral arteries will be calculated. The aorta are visualized, and the diameter is measured in ascending, arcus, descending and abdominal, and if possible in the iliac arteries. Further the heart rhythm during the CT scan is evaluated.
- Bilateral blood pressure will be recorded three times after 5 minutes of supine rest, and concurrently the ankle blood pressure are measured.
- The HbA1c and lipid parameters will be measured. Biobank blood samples are then taken, centrifuged, labelled, cooled, and stored at -80 degrees Celsius.
Follow-up visit after screening If the CAC is above the median or if an aneurism of peripheral arterial disease are detected the participant is informed of the finding and its implications at a follow-up visit. At this visit, the patient will be recommended suitable prophylactic measures, including smoking cessation, walking/exercise, a lowfat diet. Additionally to start treatment with aspirin 75 mg/day and atorvastatin 40 mg/day. If an aneurism is large the patient is referred vascular surgical assessment for the repair. Otherwise, an annual check-up of the aneurism including a CT scan will be offered. If no positive findings (CAC above the median, aneurysm or PAD) are detected, the participants will be informed of the findings by e-mail or ordinary post as preferred.
Independent of the above findings, the patients will be encouraged to see their GP for further assessment if potential undiagnosed hypertension (systolic blood pressure >160 mmHg), diabetes mellitus (HbA1c >48 mmol/mol), or significant isolated hypercholesterolemia (total-cholesterol >8.0 mmol/l) are observed, as possible continuous medical treatments will be better managed by the GPs.
The GPs will be informed by a letter of all negative and positive results and the initiated actions. Additionally in the FISICH-I trial, four further randomizations are performed. In the written invitations to the screening examination two further randomizations are performed;
- prebooking versus active booking
- +/- addition of illustrations of the examinations during the screening session.
Power calculations and Randomisations
Randomisation will be performed in SPSS by providing each individual a random number from 1-20. Those numbered +16 will be invited to participate in the screening program. Those numbered 17 and 18 will be prebooked, while those numbered 19 and 20 will have to book themselves through web-booking, email or phone.
Those with an equal number (18 and 20) will receive supplemental informative pictures of the screening session.
In case of positive finding a new random number from 1-4 is given. Those numbered 3 and 4 will be confronted with imaging of their own arterial lesions, whilst others will receive standard information. Those with an equal number (2 and 4) will receive a SMS, e-mail and phone call 3 \& 12 months after the consultation. If all groups after randomisations are equally sized,- 182 will only be additionally randomized to be remembered prescription renewal after 3 and 12 months, and 182 will only have been randomized to the standard of booking (Control group for all invited). If 12 months compliance to initiated preventive medication is 66%, then with 0.05 significance level, and 80% power, the smallest difference detectable is 15%, which seems clinical relevant. However, merged analyses adjusting for the other interventions will be performed reducing the smallest detectable difference and reveal potential synergistic combinations. Similar group comparisons will be performed for all randomized interventions.
Baseline variables Age, smoking, previous or current stroke, ischemic heart disease, PAD, chronic obstructive pulmonary disease, diabetes, hypertension, use of statins, useof antithrombotics, body mass index, systolic- and diastolic blood pressure, ankle brachial index, marital status, highest educational level, personal- andin house income, psychiatric morbidity defined as any diagnosis and/or use of medications for mental illness, and QoL.
Baseline and outcome variables from national registries The CPR number assigned to Danish citizens enables individual-level linkage to multiple nation-wide healthcare and administrative registries which have proved valid.
Registry-based information on outpatient visits, hospitals admissions and procedures (The Danish National Patient Registry), relevant prescribed drugs dispensed (The Danish National Prescription Registry), socio economic status etc. (Registries at Statistics Denmark) and primary care service use (National Health Insurance Service Registry) will be obtained.
Outcomes The primary outcomes are
- Attendance to screening
- One-year adherence to initiated lipid-lowering and/or antithrombotic medication.
Secondary outcome is:
- QoL,
Statistical analysis Baseline characteristics will be analysed using conventional summary statistics.
Attendance rates adjusted for invitation layout and booking-method, as well as compliance one year after initiation (def.: received a prescription 9-12 months after the consultation) adjusted for image-confrontation and post-consultation phone call are compared by logistic regression analysis.
Study design
- Primary purpose
- Screening
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- None (open label)
- Number of arms
- 4
- Model description
- 2 x factorial design regarding attendance rate to cardiovacular screening
| Arm | Type | Receives |
|---|---|---|
| Prebooking | Active comparator | Behavioral: Prebooking, Behavioral: Pictured invitationParticipants randomised to this arm receives a prebooked appointment to screening |
| Web based booking | Placebo comparator | Behavioral: Prebooking, Behavioral: Pictured invitationParticipants randomised to this arm receives an invitation to book a screening appointment webbased or by contacting the trial office. |
| Pictured invitation | Active comparator | Behavioral: Prebooking, Behavioral: Pictured invitationParticipants randomised to this arm receives a pictured invitation to screening |
| Texted invitation | Placebo comparator | Behavioral: Prebooking, Behavioral: Pictured invitationParticipants randomised to this arm receives a classical texted invitation to screening |
Who may qualify
- Ages
- 60 to 65 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Men aged 60-64 living in the municipalities of Funen, Silkeborg, Vejle and surrounding municipailties
Key exclusion criteria (3 listed)
- Men not aged 60-65
- Men not living in the mentioned municipalities
- Women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PrebookingParticipants are receiving a prebooked appointment for CVD screening or being invited to book an appointment for CVD Screening | Behavioural | Pictured invitation, Prebooking, Texted invitation, Web based booking |
| Pictured invitationParticipants are receiving an illustrated invitation CVD screening or a classical text-invitation to book an appointment for CVD Screening | Behavioural | Pictured invitation, Prebooking, Texted invitation, Web based booking |
Primary outcome
Attendance rate to screening
Time frame: 6 months
The proportion of invited attending screening
1 secondary outcome
Quality of Life of invitation to screening
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2019.
- Individual participant dataSharing planned: No. Data will be analysed on Statistics Denmarks secured server
Related trials for Cardiac Disease
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Active, not recruiting
Shockwave™ vs Surgical Endarterectomy for Calcified Severe Common Femoral Artery Stenosis: Comparison of Efficacy, Safety and Long-Term Outcomes
Common Femoral Artery Stenosis, Calcification; Heart
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
RecruitingPhase 4
The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)
Heart Failure With Reduced Ejection Fraction, Iron Deficiency
Recruiting
Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
Aortic Stenosis Treated With TAVI, Aortic Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jes S Lindholt principal investigator
Odense University Hospital
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prebooking and Pictured invitation in people with Cardiac Disease and Vascular Diseases, run by Odense University Hospital at 5 sites in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 May 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Attendance rate to screening (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2019.